Literature DB >> 18319331

Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma.

Yan Ding1, Elissa A Boguslawski, Bree D Berghuis, John J Young, Zhongfa Zhang, Kim Hardy, Kyle Furge, Eric Kort, Arthur E Frankel, Rick V Hay, James H Resau, Nicholas S Duesbery.   

Abstract

We hypothesized that signaling through multiple mitogen-activated protein kinase (MAPK) kinase (MKK) pathways is essential for the growth and vascularization of soft-tissue sarcomas, which are malignant tumors derived from mesenchymal tissues. We tested this using HT-1080, NCI, and Shac fibrosarcoma-derived cell lines and anthrax lethal toxin (LeTx), a bacterial toxin that inactivates MKKs. Western blots confirmed that LeTx treatment reduced the levels of phosphorylated extracellular signal-regulated kinase and p38 MAPK in vitro. Although short treatments with LeTx only modestly affected cell proliferation, sustained treatment markedly reduced cell numbers. LeTx also substantially inhibited the extracellular release of angioproliferative factors including vascular endothelial growth factor, interleukin-8, and basic fibroblast growth factor. Similar results were obtained with cell lines derived from malignant fibrous histiocytomas, leiomyosarcomas, and liposarcomas. In vivo, LeTx decreased MAPK activity and blocked fibrosarcoma growth. Growth inhibition correlated with decreased cellular proliferation and extensive necrosis, and it was accompanied by a decrease in tumor mean vessel density as well as a reduction in serum expression of angioproliferative cytokines. Vital imaging using high-resolution ultrasound enhanced with contrast microbubbles revealed that the effects of LeTx on tumor perfusion were remarkably rapid (<24 h) and resulted in a marked reduction of perfusion within the tumor but not in nontumor tissues. These results are consistent with our initial hypothesis and lead us to propose that MKK inhibition by LeTx is a broadly effective strategy for targeting neovascularization in fibrosarcomas and other similar proliferative lesions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18319331     DOI: 10.1158/1535-7163.MCT-07-2229

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  16 in total

1.  Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.

Authors:  Susan K Mathai; Mridu Gulati; Xueyan Peng; Thomas R Russell; Albert C Shaw; Ami N Rubinowitz; Lynne A Murray; Jonathan M Siner; Danielle E Antin-Ozerkis; Ruth R Montgomery; Ronald A S Reilkoff; Richard J Bucala; Erica L Herzog
Journal:  Lab Invest       Date:  2010-04-19       Impact factor: 5.662

2.  3-D microvessel-mimicking ultrasound phantoms produced with a scanning motion system.

Authors:  Ryan C Gessner; Roshni Kothadia; Steven Feingold; Paul A Dayton
Journal:  Ultrasound Med Biol       Date:  2011-03-25       Impact factor: 2.998

3.  Anthrax lethal toxin suppresses high glucose induced VEGF over secretion through a post-translational mechanism.

Authors:  Wei-Wei Zhang; Xin Wang; Ping Xie; Song-Tao Yuan; Qing-Huai Liu
Journal:  Int J Ophthalmol       Date:  2015-06-18       Impact factor: 1.779

4.  Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.

Authors:  Randall W Alfano; Stephen H Leppla; Shihui Liu; Thomas H Bugge; Janelle M Ortiz; Terry C Lairmore; Nicholas S Duesbery; Ian C Mitchell; Fiemu Nwariaku; Arthur E Frankel
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

5.  Perturbation of mouse retinal vascular morphogenesis by anthrax lethal toxin.

Authors:  Jennifer L Bromberg-White; Elissa Boguslawski; Nicholas S Duesbery
Journal:  PLoS One       Date:  2009-09-14       Impact factor: 3.240

6.  Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesis.

Authors:  Randall W Alfano; Stephen H Leppla; Shihui Liu; Thomas H Bugge; Cynthia J Meininger; Terry C Lairmore; Arlynn F Mulne; Samuel H Davis; Nicholas S Duesbery; Arthur E Frankel
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

Review 7.  Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy.

Authors:  Lorna M Cryan; Michael S Rogers
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01

8.  The molecular biology of soft-tissue sarcomas and current trends in therapy.

Authors:  Jorge Quesada; Robert Amato
Journal:  Sarcoma       Date:  2012-05-10

Review 9.  Consequences and utility of the zinc-dependent metalloprotease activity of anthrax lethal toxin.

Authors:  Jennifer Bromberg-White; Chih-Shia Lee; Nicholas Duesbery
Journal:  Toxins (Basel)       Date:  2010-05-11       Impact factor: 4.546

10.  Vector-mediated selective expression of lethal factor, a toxic element of Bacillus anthracis, damages A549 cells via inhibition of MAPK and AKT pathways.

Authors:  Wenlei Zhuo; Guangli Tao; Liang Zhang; Zhengtang Chen
Journal:  Int J Med Sci       Date:  2013-01-27       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.